Review



human vcam 1 fc  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems human vcam 1 fc
    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 <t>μg/ml</t> <t>VCAM-1</t> Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Human Vcam 1 Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 39 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+vcam/Recombinant+Human+VCAM-1%2FCD106+Fc+Chimera+Protein%2C+CF/pmc12810549-217-46-49
    Average 94 stars, based on 39 article reviews
    human vcam 1 fc - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "A CD25–chemokine receptor complex initiates noncanonical IL-2 signaling"

    Article Title: A CD25–chemokine receptor complex initiates noncanonical IL-2 signaling

    Journal: The Journal of Biological Chemistry

    doi: 10.1016/j.jbc.2025.110981

    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 μg/ml VCAM-1 Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Figure Legend Snippet: hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 μg/ml VCAM-1 Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.

    Techniques Used: Activation Assay, Expressing, Incubation, Control, Flow Cytometry, Fluorescence, Staining, Transfection, SDS Page, Western Blot

    HS induces an IL-2-dependent CD25–CCR7 complex to trigger MACS. A, IL-2(E52K) does not support HS-induced CD25–CCR7 association. Membrane lysates from HA-hCD25–expressing HEK293T cells were incubated with 5 μg/ml HS in the presence (+) or absence (−) of 2.5 μg/ml IL-2 (WT) or IL-2 (E52K) for 30 min at 37 °C. Anti-HA immunoprecipitates were fractionated by SDS-PAGE, and blots were probed with either anti-HA or anti-CCR7. Quantification of data by LI-COR infrared spectroscopy from three independent experiments is shown to the righ t of the blot. B, IL-2(E52K) does not support HS-induced integrin activation. hCD25-Jurkat cells were incubated with 5 μg/ml HS in the presence or the absence (−) of 2.5 μg/ml IL2 (WT) or IL-2(E52K) and 5 μg/ml VCAM-1 for 30 min at 37 °C, and bound VCAM-1 was measured by flow cytometry. C, HS-induced CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 40 μg/ml HS and/or buffer control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound MAdCAM-1 Fc by flow cytometry. D, HS did not affect canonical IL-2 signaling. IL-2Rα + YT-1 cells were incubated with varying concentrations of IL-2 WT in the presence ( blue ) or the absence (0, black ) of 40 μg/ml HS for 30 min at 37 o C followed by analysis of phospho-STAT5 staining by flow cytometry. Curves were fitted to a simple agonist response model by nonlinear regression on GraphPad Prism, version 10. ∗ p < 0.05, ∗∗ p < 0.01 by unpaired t tests ( A ) or one-way ANOVA with Tukey’s correction ( B , C ), mean ± SEM from at least three independent experiments. HA, hemagglutinin; hCD25, human C25; HEK293T, human embryonic kidney 293T cell line; HS, heparan sulfate; IL-2, interleukin 2; MACS, monoclonal antibody (or matrix)–directed alternative cytokine signalling; STAT5, signal transducer and activator of transcription 5; VCAM-1, vascular cell adhesion molecule 1.
    Figure Legend Snippet: HS induces an IL-2-dependent CD25–CCR7 complex to trigger MACS. A, IL-2(E52K) does not support HS-induced CD25–CCR7 association. Membrane lysates from HA-hCD25–expressing HEK293T cells were incubated with 5 μg/ml HS in the presence (+) or absence (−) of 2.5 μg/ml IL-2 (WT) or IL-2 (E52K) for 30 min at 37 °C. Anti-HA immunoprecipitates were fractionated by SDS-PAGE, and blots were probed with either anti-HA or anti-CCR7. Quantification of data by LI-COR infrared spectroscopy from three independent experiments is shown to the righ t of the blot. B, IL-2(E52K) does not support HS-induced integrin activation. hCD25-Jurkat cells were incubated with 5 μg/ml HS in the presence or the absence (−) of 2.5 μg/ml IL2 (WT) or IL-2(E52K) and 5 μg/ml VCAM-1 for 30 min at 37 °C, and bound VCAM-1 was measured by flow cytometry. C, HS-induced CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 40 μg/ml HS and/or buffer control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound MAdCAM-1 Fc by flow cytometry. D, HS did not affect canonical IL-2 signaling. IL-2Rα + YT-1 cells were incubated with varying concentrations of IL-2 WT in the presence ( blue ) or the absence (0, black ) of 40 μg/ml HS for 30 min at 37 o C followed by analysis of phospho-STAT5 staining by flow cytometry. Curves were fitted to a simple agonist response model by nonlinear regression on GraphPad Prism, version 10. ∗ p < 0.05, ∗∗ p < 0.01 by unpaired t tests ( A ) or one-way ANOVA with Tukey’s correction ( B , C ), mean ± SEM from at least three independent experiments. HA, hemagglutinin; hCD25, human C25; HEK293T, human embryonic kidney 293T cell line; HS, heparan sulfate; IL-2, interleukin 2; MACS, monoclonal antibody (or matrix)–directed alternative cytokine signalling; STAT5, signal transducer and activator of transcription 5; VCAM-1, vascular cell adhesion molecule 1.

    Techniques Used: Membrane, Expressing, Incubation, SDS Page, Spectroscopy, Activation Assay, Flow Cytometry, Control, Staining

    Related Articles

    Recombinant:

    Article Title: Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis
    Article Snippet: Collagen IV (from bovine placenta villi) was purchased from Chemicon Temecula, CA, and Collagen I (from rat tail) was purchased from BD Biosciences (Bedford, MA). .. Recombinant Human VCAM-1 was purchased from PeproTech Co. (Rehovot, Israel), and recombinant human VCAM-1/CD106 Fc and MAdCAM-1 Fc chimeras, as well as recombinant human integrin α4β1 or α4β7 were obtained from R&D Systems Co (Minneapolis, MN). .. Human fibronectin and laminin were purchased from Sigma-Aldrich Israel Ltd. (Rehovot, Israel).

    Article Title: VLA-4 Induces Chemoresistance of T Cell Acute Lymphoblastic Leukemia Cells via PYK2-Mediated Drug Efflux
    Article Snippet: .. Recombinant human VCAM-1/CD106 Protein and Recombinant Human/Rhesus Macaque/Feline CXCL12/SDF1α were from R&D Systems (Minneapolis, MN, USA). .. Human fibronectin, doxorubicin and FAK inhibitor PF-228 were purchased from Millipore Sigma (Oakville, ON, Canada).

    Article Title: A method to estimate the effective point spread function of static single molecule localization microscopy images
    Article Snippet: .. Wells were rinsed with PBS, then nonspecific binding was blocked with 2% BSA at room temperature for 10 minutes, followed by incubation with 0.01 mg/mL recombinant human VCAM-1/CD106 Fc chimera protein (R&D Systems) and 0.01 mg/mL ChromPure Human IgG, Fc fragment (Jackson Immunoresearch) for 1 hour at room temperature or overnight at 4°C. ..

    Article Title: Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.
    Article Snippet: Collagen IV (from bovine placenta villi) was purchased from Chemicon Temecula, CA, and Collagen I (from rat tail) was purchased from BD Biosciences (Bedford, MA). .. Recombinant Human VCAM-1 was purchased from PeproTech Co. (Rehovot, Israel), and recombinant human VCAM-1/CD106 Fc and MAdCAM-1 Fc chimeras, as well as recombinant human integrin α4β1 or α4β7 were obtained from R&D Systems Co (Minneapolis, MN). .. Human fibronectin and laminin were purchased from SigmaAldrich Israel Ltd. (Rehovot, Israel).

    Article Title: Cell adhesion to collagen promotes leukemia resistance to doxorubicin by reducing DNA damage through the inhibition of Rac1 activation.
    Article Snippet: The Rac1 inhibitor (NSC23766) was obtained from Tocris Bioscience (Ellisville, MO, USA). .. Recombinant human VCAM-1/CD106 protein was from R&D systems (Minneapolis, MN, USA). .. The anti-caspase-3 (E-8) that detects the native and the active fragments of caspase-3, anti-Mcl-1 (22) and anti-β-actin (C-2) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

    Binding Assay:

    Article Title: A method to estimate the effective point spread function of static single molecule localization microscopy images
    Article Snippet: .. Wells were rinsed with PBS, then nonspecific binding was blocked with 2% BSA at room temperature for 10 minutes, followed by incubation with 0.01 mg/mL recombinant human VCAM-1/CD106 Fc chimera protein (R&D Systems) and 0.01 mg/mL ChromPure Human IgG, Fc fragment (Jackson Immunoresearch) for 1 hour at room temperature or overnight at 4°C. ..

    Incubation:

    Article Title: A method to estimate the effective point spread function of static single molecule localization microscopy images
    Article Snippet: .. Wells were rinsed with PBS, then nonspecific binding was blocked with 2% BSA at room temperature for 10 minutes, followed by incubation with 0.01 mg/mL recombinant human VCAM-1/CD106 Fc chimera protein (R&D Systems) and 0.01 mg/mL ChromPure Human IgG, Fc fragment (Jackson Immunoresearch) for 1 hour at room temperature or overnight at 4°C. ..

    other:

    Article Title: Cell adhesion to collagen promotes leukemia resistance to doxorubicin by reducing DNA damage through the inhibition of Rac1 activation
    Article Snippet: Collagen type I, fibronectin and doxorubicin were purchased from Millipore-Sigma (Billerica, MA, USA).

    Article Title: MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest.
    Article Snippet: Antibodies and Reagents Antibody Source Host Species Usage Rabbit isotype control Immunostep (Salamanca, Spain) Rabbit FACS Mouse isotype control BD Pharmigen (Franklin Lakes, NJ, USA) Mouse FACS MMP-9 (sc-6841R) Santa Cruz Biotech. (Santa Cruz, CA, USA) Rabbit WB, FACS CD52 (sc-51560) Santa Cruz Biotechnology Mouse WB, FACS CD226 (sc-53581) Santa Cruz Biotechnology Mouse WB, FACS CD99 (#1850, clone DN16) Bio-Rad (Hercules, CA, USA) Mouse WB, FACS CD99 (#sc-53148, clone 12E7) Santa Cruz Biotechnology Mouse WB CD274 (#14-5983) Affymetrix eBioscience (San Diego, CA, USA) Mouse WB, FACS CXCR3 (#353718) BioLegend (San Diego, CA, USA) Mouse WB, FACS CD38 (16BDH) Dr. F. Sánchez-Madrid (Madrid, Spain) Mouse FACS α4 integrin (HP2/1) Dr. F. Sánchez-Madrid Mouse FACS Phospho-p65 (S536, #3033) Cell Signalling Tech. (Danvers, MA, USA) Rabbit WB Phospho-Sp1 (T453, #37707) Abcam (Cambridge, UK) Rabbit WB Vinculin (#V9131) Sigma-Aldrich (St. Louis, MO, USA) Mouse WB Alexa 488-anti-mouse Igs Molecular Probes (Eugene, OR, USA) Goat FACS Alexa 647-anti-mouse Igs Molecular Probes Goat FACS HRP-anti-mouse Igs DAKO Corporation (Hamburg, Germany) Goat WB HRP-anti-rabbit Igs DAKO Corporation Goat WB Reagent Source TNF- R&D Systems (Minneapolis, MN, USA) Recombinant human VCAM-1/CD106 Fc chimera R&D Systems CCL21 Peprotech EC (London, UK) Fibronectin FN-H89 fragment (contains the CS1 ligand for 41 integrin) Prepared as described2 Mithramycin Sigma-Aldrich NFB inhibitor Calbiochem (Darmstadt, Germany) Supplementary Methods Gene expression analysis by microarrays 3x106 MEC-1 cell transfectants were cultured in IMDM/0.1% FBS for 2 h and total RNA extracted and purified using the Allprep® DNA/RNA/Protein kit (Qiagen, Hilden, Germany).



    Similar Products

    human vcam 1 fc  (R&D Systems)
    94
    R&D Systems human vcam 1 fc
    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 <t>μg/ml</t> <t>VCAM-1</t> Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Human Vcam 1 Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+vcam/Recombinant+Human+VCAM-1%2FCD106+Fc+Chimera+Protein%2C+CF/pmc12810549-217-46-49
    Average 94 stars, based on 1 article reviews
    human vcam 1 fc - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    recombinant human vascular cell adhesion molecules  (R&D Systems)
    93
    R&D Systems recombinant human vascular cell adhesion molecules
    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 <t>μg/ml</t> <t>VCAM-1</t> Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Recombinant Human Vascular Cell Adhesion Molecules, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+vcam/Recombinant+Human+VCAM-1%2FCD106+Protein%2C+CF/pm23590123__ja400636d_si_001-33-13-20
    Average 93 stars, based on 1 article reviews
    recombinant human vascular cell adhesion molecules - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    recombinant human vcam-1  (PeproTech)
    90
    PeproTech recombinant human vcam-1
    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 <t>μg/ml</t> <t>VCAM-1</t> Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Recombinant Human Vcam 1, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+vcam/mip+1+gamma/bio_rxiv__2025__07__11__664379-37-16-19
    Average 90 stars, based on 1 article reviews
    recombinant human vcam-1 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    vcam 1  (R&D Systems)
    94
    R&D Systems vcam 1
    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 <t>μg/ml</t> <t>VCAM-1</t> Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Vcam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+vcam/Recombinant+Human+VCAM-1%2FCD106+Fc+Chimera+Protein%2C+CF/bio_rxiv__2025__07__11__664494-204-0-1
    Average 94 stars, based on 1 article reviews
    vcam 1 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    recombinant vcam 1 fc fusion protein  (R&D Systems)
    93
    R&D Systems recombinant vcam 1 fc fusion protein
    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 <t>μg/ml</t> <t>VCAM-1</t> Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Recombinant Vcam 1 Fc Fusion Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+vcam/Recombinant+Human+VCAM-1%2FCD106+Protein%2C+CF/us12338460-295-0-7
    Average 93 stars, based on 1 article reviews
    recombinant vcam 1 fc fusion protein - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    vascular cell adhesion molecule vcam 1  (R&D Systems)
    93
    R&D Systems vascular cell adhesion molecule vcam 1
    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 <t>μg/ml</t> <t>VCAM-1</t> Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.
    Vascular Cell Adhesion Molecule Vcam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+vcam/Recombinant+Human+VCAM-1%2FCD106+Protein%2C+CF/pm40051617-137-24-29
    Average 93 stars, based on 1 article reviews
    vascular cell adhesion molecule vcam 1 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 μg/ml VCAM-1 Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.

    Journal: The Journal of Biological Chemistry

    Article Title: A CD25–chemokine receptor complex initiates noncanonical IL-2 signaling

    doi: 10.1016/j.jbc.2025.110981

    Figure Lengend Snippet: hCD25–chemokine receptor complex triggers integrin activation. A and B, IL-2(E52K) does not trigger MACS-dependent integrin activation in a CD25-expressing T-cell line or Tregs. A, hCD25-Jurkat T cells or ( B ) primary human Tregs were incubated with 5 μg/ml VCAM-1 Fc (these cells express primarily α4β1 rather than α4β7) and 5 μg/ml 7G7B6 or isotype control in the presence or the absence of 1 μg/ml IL-2(WT) or IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry. C, IL2RA + -YT1 cells express ∼8-fold more CCR5 than hCD25 Jurkat T cells. Depicted are flow cytometry histograms and geometric mean fluorescence intensity of staining with anti-CCR5 or isotype control antibody. D, a CCR5 antagonist blocks assembly of the 7G7B6-induced CD25–CCR5 complex. HEK293T-HA-hCD25 cells were transfected with cDNA encoding the indicated FLAG-tagged chemokine receptor and then incubated with 5 μg/ml 7G7B6 and 1 μg/ml IL-2 (WT), IL-2(E52K), or IL-2(E52K)+ 50 nM maraviroc for 1 h at 37 °C. Cells were lysed, and immunoprecipitates were fractionated by SDS-PAGE followed by immunoblotting for HA-hCD25 ( E ) 7G7B6-induced the CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells (express α4β7) were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 5 μg/ml 7G7B6 and/or isotype control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), or 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound VCAM-1 Fc by flow cytometry: ∗ p < 0.05, ∗∗ p < 0.01, by one-way ANOVA with Tukey’s correction, Scatter plots depict mean (horizontal line) from at least three independent experiments. cDNA, complementary DNA; HA, hemagglutinin; hCD25, human CD25; HEK293T, human embryonic kidney 293T cell line; IL-2, interleukin 2; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1.

    Article Snippet: Cells were plated in a 96-well plate and incubated with the following ligands for 30 min at 37 °C in Hanks' balanced salt solution (HBSS) with Ca/Mg (Gibco; catalog no.: 14-025-092): 5 μg/ml human MAdCAM-1 Fc (R&D Systems; catalog no.: 6056-MC) for YT-1 hCD25 cells or human VCAM-1 Fc (R&D Systems; catalog no.: 862-VC) with human primary CD4 + T cells, 0.5 μg/ml IL-2, 10 μg/ml IgG control or 7G7B6, 5 μg/ml HS, 200 ng/ml pertussis toxin, 100 nM phorbol 12-myristate 13-acetate (Sigma; catalog no.: P8139), and 10 mM EDTA (Invitrogen; catalog no.: AM9260G).

    Techniques: Activation Assay, Expressing, Incubation, Control, Flow Cytometry, Fluorescence, Staining, Transfection, SDS Page, Western Blot

    HS induces an IL-2-dependent CD25–CCR7 complex to trigger MACS. A, IL-2(E52K) does not support HS-induced CD25–CCR7 association. Membrane lysates from HA-hCD25–expressing HEK293T cells were incubated with 5 μg/ml HS in the presence (+) or absence (−) of 2.5 μg/ml IL-2 (WT) or IL-2 (E52K) for 30 min at 37 °C. Anti-HA immunoprecipitates were fractionated by SDS-PAGE, and blots were probed with either anti-HA or anti-CCR7. Quantification of data by LI-COR infrared spectroscopy from three independent experiments is shown to the righ t of the blot. B, IL-2(E52K) does not support HS-induced integrin activation. hCD25-Jurkat cells were incubated with 5 μg/ml HS in the presence or the absence (−) of 2.5 μg/ml IL2 (WT) or IL-2(E52K) and 5 μg/ml VCAM-1 for 30 min at 37 °C, and bound VCAM-1 was measured by flow cytometry. C, HS-induced CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 40 μg/ml HS and/or buffer control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound MAdCAM-1 Fc by flow cytometry. D, HS did not affect canonical IL-2 signaling. IL-2Rα + YT-1 cells were incubated with varying concentrations of IL-2 WT in the presence ( blue ) or the absence (0, black ) of 40 μg/ml HS for 30 min at 37 o C followed by analysis of phospho-STAT5 staining by flow cytometry. Curves were fitted to a simple agonist response model by nonlinear regression on GraphPad Prism, version 10. ∗ p < 0.05, ∗∗ p < 0.01 by unpaired t tests ( A ) or one-way ANOVA with Tukey’s correction ( B , C ), mean ± SEM from at least three independent experiments. HA, hemagglutinin; hCD25, human C25; HEK293T, human embryonic kidney 293T cell line; HS, heparan sulfate; IL-2, interleukin 2; MACS, monoclonal antibody (or matrix)–directed alternative cytokine signalling; STAT5, signal transducer and activator of transcription 5; VCAM-1, vascular cell adhesion molecule 1.

    Journal: The Journal of Biological Chemistry

    Article Title: A CD25–chemokine receptor complex initiates noncanonical IL-2 signaling

    doi: 10.1016/j.jbc.2025.110981

    Figure Lengend Snippet: HS induces an IL-2-dependent CD25–CCR7 complex to trigger MACS. A, IL-2(E52K) does not support HS-induced CD25–CCR7 association. Membrane lysates from HA-hCD25–expressing HEK293T cells were incubated with 5 μg/ml HS in the presence (+) or absence (−) of 2.5 μg/ml IL-2 (WT) or IL-2 (E52K) for 30 min at 37 °C. Anti-HA immunoprecipitates were fractionated by SDS-PAGE, and blots were probed with either anti-HA or anti-CCR7. Quantification of data by LI-COR infrared spectroscopy from three independent experiments is shown to the righ t of the blot. B, IL-2(E52K) does not support HS-induced integrin activation. hCD25-Jurkat cells were incubated with 5 μg/ml HS in the presence or the absence (−) of 2.5 μg/ml IL2 (WT) or IL-2(E52K) and 5 μg/ml VCAM-1 for 30 min at 37 °C, and bound VCAM-1 was measured by flow cytometry. C, HS-induced CCR5–CD25 complex triggers integrin activation. IL2RA + -YT1 cells were incubated with 5 μg/ml MAdCAM-1 Fc in the presence or the absence of 40 μg/ml HS and/or buffer control (0) in the presence or the absence of 1 μg/ml IL-2, IL-2(E52K), 50 nM maraviroc (Mara) + IL-2(E52K) for 30 min at 37 °C before measurement of bound MAdCAM-1 Fc by flow cytometry. D, HS did not affect canonical IL-2 signaling. IL-2Rα + YT-1 cells were incubated with varying concentrations of IL-2 WT in the presence ( blue ) or the absence (0, black ) of 40 μg/ml HS for 30 min at 37 o C followed by analysis of phospho-STAT5 staining by flow cytometry. Curves were fitted to a simple agonist response model by nonlinear regression on GraphPad Prism, version 10. ∗ p < 0.05, ∗∗ p < 0.01 by unpaired t tests ( A ) or one-way ANOVA with Tukey’s correction ( B , C ), mean ± SEM from at least three independent experiments. HA, hemagglutinin; hCD25, human C25; HEK293T, human embryonic kidney 293T cell line; HS, heparan sulfate; IL-2, interleukin 2; MACS, monoclonal antibody (or matrix)–directed alternative cytokine signalling; STAT5, signal transducer and activator of transcription 5; VCAM-1, vascular cell adhesion molecule 1.

    Article Snippet: Cells were plated in a 96-well plate and incubated with the following ligands for 30 min at 37 °C in Hanks' balanced salt solution (HBSS) with Ca/Mg (Gibco; catalog no.: 14-025-092): 5 μg/ml human MAdCAM-1 Fc (R&D Systems; catalog no.: 6056-MC) for YT-1 hCD25 cells or human VCAM-1 Fc (R&D Systems; catalog no.: 862-VC) with human primary CD4 + T cells, 0.5 μg/ml IL-2, 10 μg/ml IgG control or 7G7B6, 5 μg/ml HS, 200 ng/ml pertussis toxin, 100 nM phorbol 12-myristate 13-acetate (Sigma; catalog no.: P8139), and 10 mM EDTA (Invitrogen; catalog no.: AM9260G).

    Techniques: Membrane, Expressing, Incubation, SDS Page, Spectroscopy, Activation Assay, Flow Cytometry, Control, Staining